
    
      The core study duration was approximately 35 weeks per participant (screening: 3 weeks,
      double-blind treatment period: 24 weeks; follow-up: 8 weeks). Participants who successfully
      completed the treatment period had the possibility to participate in an optional open-label
      treatment period with Alirocumab 150 mg Q4W until second quarter 2017 or until the drug is
      commercially available in the country, whatever occurred first.
    
  